Alteogen在ObesityWeek 2026上公布了其超长效平台ALT-M5的临床前研究结果。数据显示,该药物在减重效果、半衰期及停药后体重反弹抑制方面均优于礼来公司的Retatrutide,展现了开发月度注射剂的潜力。
Alteogen挑战月度减肥针:动物实验减重效果优于礼来新药
Alteogen在ObesityWeek 2026上公布了其超长效平台ALT-M5的临床前研究结果。数据显示,该药物在减重效果、半衰期及停药后体重反弹抑制方面均优于礼来公司的Retatrutide,展现了开发月度注射剂的潜力。
-6-800x600.webp)
MTIMES Global Editorial Statement
This analysis is provided for international business intelligence and informational purposes only. It does not constitute investment advice or a solicitation to buy or sell securities. For inquiries regarding licensing or syndication, please contact [email protected].






